480 related articles for article (PubMed ID: 16098844)
1. An approach to heart failure and diabetes mellitus.
Fonarow GC
Am J Cardiol; 2005 Aug; 96(4A):47E-52E. PubMed ID: 16098844
[TBL] [Abstract][Full Text] [Related]
2. Managing the patient with diabetes mellitus and heart failure: issues and considerations.
Fonarow GC
Am J Med; 2004 Mar; 116 Suppl 5A():76S-88S. PubMed ID: 15019865
[TBL] [Abstract][Full Text] [Related]
3. The management of the diabetic patient with prior cardiovascular events.
Fonarow GC
Rev Cardiovasc Med; 2003; 4 Suppl 6():S38-49. PubMed ID: 14668702
[TBL] [Abstract][Full Text] [Related]
4. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
Pitt B; Fonarow GC; Gheorghiade M; Deedwania PC; Duprez DA
Am J Cardiol; 2006 May; 97(10A):26F-33F. PubMed ID: 16698332
[TBL] [Abstract][Full Text] [Related]
5. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG
Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692
[TBL] [Abstract][Full Text] [Related]
6. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
[TBL] [Abstract][Full Text] [Related]
7. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
Azadpour M; Lamas GA
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
[TBL] [Abstract][Full Text] [Related]
8. Type 2 diabetes mellitus and heart failure.
Choy CK; Rodgers JE; Nappi JM; Haines ST
Pharmacotherapy; 2008 Feb; 28(2):170-92. PubMed ID: 18225964
[TBL] [Abstract][Full Text] [Related]
9. Importance of in-hospital initiation of evidence-based medical therapies for heart failure-a review.
Fonarow GC; Gheorghiade M; Abraham WT
Am J Cardiol; 2004 Nov; 94(9):1155-60. PubMed ID: 15518610
[TBL] [Abstract][Full Text] [Related]
10. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
Dulin BR; Krum H
Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological therapy of chronic heart failure in the elderly].
Sabbadini G; Di Lenarda A; Metra M; Nodari S; Moretti M; Brentana L; Dei Cas L; Sinagra G
Ital Heart J; 2004 Dec; 5 Suppl 10():37S-51S. PubMed ID: 15712511
[TBL] [Abstract][Full Text] [Related]
13. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure).
Krantz MJ; Ambardekar AV; Kaltenbach L; Hernandez AF; Heidenreich PA; Fonarow GC;
Am J Cardiol; 2011 Jun; 107(12):1818-23. PubMed ID: 21482418
[TBL] [Abstract][Full Text] [Related]
14. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
Diercks GF; Overdiek JW; van Veldhuisen DJ
Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145
[TBL] [Abstract][Full Text] [Related]
15. [Recent advances and limitations of medical treatment on heart failure].
Momomura S
Kyobu Geka; 2007 Jun; 60(6):484-7. PubMed ID: 17564066
[TBL] [Abstract][Full Text] [Related]
16. How well are chronic heart failure patients being managed?
Fonarow GC
Rev Cardiovasc Med; 2006; 7 Suppl 1():S3-11. PubMed ID: 16955055
[TBL] [Abstract][Full Text] [Related]
17. Heart failure: recent advances in prevention and treatment.
Fonarow GC
Rev Cardiovasc Med; 2000; 1(1):25-33, 54. PubMed ID: 12457149
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic advances in long-term heart failure management.
Pfeffer MA
Am Heart Hosp J; 2004; 2(4 Suppl 1):15-20. PubMed ID: 15539971
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
20. [Is it always necessary to use triple combination in the treatment of patients with chronic cardiac failure? Choice of the third neurohormonal blocker].
Belenkov IuN; Mareev VIu; Skvortsov AA
Ter Arkh; 2008; 80(9):5-12. PubMed ID: 19555028
[No Abstract] [Full Text] [Related]
[Next] [New Search]
